Neuroendocrine Tumor, NOS
Back to Diseases List
Associated Genetic Biomarkers
Neuroendocrine tumor, NOSs most frequently harbor alterations in TP53, MEN1, KMT2D, FAT1, and ARID1A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KMT2D Mutation, and FAT1 Mutation are the most common alterations in neuroendocrine tumor, NOS .
There are 2 clinical trials for neuroendocrine tumor, NOS, of which 2 are open and 0 are completed or closed. Of the trials that contain neuroendocrine tumor, NOS as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
SSTR2 is the most frequent gene inclusion criterion for neuroendocrine tumor, NOS clinical trials .
Cabozantinib, lanreotide, and tidutamab are the most common interventions in neuroendocrine tumor, NOS clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.